ULTRA-SENSITIVE PROTEOMICS · ALAMAR CERTIFIED SERVICE PROVIDER
Proteins conventional immunoassays cannot reach
Proteins conventional immunoassays cannot reach
Attomolar sensitivity. Up to 340 targets in a single run. From 25 µL of plasma, serum or CSF, and from specialist matrices beyond the standard three. Data back in two weeks.
We run NULISA end to end in our own laboratory, sequencing included.
Attomolar sensitivity. Up to 340 targets in a single run. From 25 µL of plasma, serum or CSF, and from specialist matrices beyond the standard three. Data back in two weeks.
We run NULISA end to end in our own laboratory, sequencing included.
1 of 5
laboratories worldwide
Alamar-certified for custom assay development
1 of 5 laboratories worldwide
Alamar-certified for custom assay development
1 of 5 laboratories worldwide
Alamar-certified for custom assay development
Data in
2 weeks, not months
Data in
2 weeks, not months
Data in 2 weeks, not months
ARGO™ HT and Element AVITI™ under one roof
ARGO™ HT and
Element AVITI™ under one roof
ARGO™ HT and Element AVITI™ under one roof
HTA licensed, GCP compliant
HTA licensed, GCP compliant
Alamar Certified Service Provider
Alamar Certified Service Provider
WHAT IS NULISA™
A new floor for protein detection
For decades some of the most biologically informative proteins have sat below the detection limit of conventional immunoassays:
low-abundance signalling molecules
early markers of disease
targets that move first when therapy starts working
NULISA, the NUcleic acid Linked Immuno-Sandwich Assay, changes that. A sequential capture-and-release mechanism suppresses assay background by around 10,000-fold compared with traditional proximity ligation, moving detection into the attomolar range, or low to sub-fg/mL.
Historically you chose between sensitivity and breadth. NULISA gives you both: up to 340 targets in a single run, with the low-abundance proteins still measurable.
Certification means your study runs on the ARGO™ HT automated system using Alamar's curated panels, with our scientists on it from the first conversation.
NULISA, the NUcleic acid Linked Immuno-Sandwich Assay, changes that. A sequential capture-and-release mechanism suppresses assay background by around 10,000-fold compared with traditional proximity ligation, moving detection into the attomolar range, or low to sub-fg/mL.
Historically you chose between sensitivity and breadth. NULISA gives you both: up to 340 targets in a single run, with the low-abundance proteins still measurable.
Certification means your study runs on the ARGO™ HT automated system using Alamar's curated panels, with our scientists on it from the first conversation.
NULISA, the NUcleic acid Linked Immuno-Sandwich Assay, changes that.
A sequential capture-and-release mechanism suppresses assay background by around 10,000-fold compared with traditional proximity ligation, moving detection into the attomolar range, or low to sub-fg/mL.
Historically you chose between sensitivity and breadth. NULISA gives you both: up to 340 targets in a single run, with the low-abundance proteins still measurable.
Certification means your study runs on the ARGO™ HT automated system using Alamar's curated panels, with our scientists on it from the first conversation.
WHY NULISA™
Specifications at a glance
Platform
NULISA on the ARGO HT automated system
Readouts
NGS for high-plex panels, run in-house on Element AVITI. qPCR for single- and low-plex assays
Up to 1,000-fold greater than conventional ELISA.
Femtogram-per-millilitre for many targets.
SR-X performance figures confirmed per assay at scoping
Multiplexing
1 to approximately 340 targets per sample
1 to approximately 340 targets per sample
Sensitivity
Attomolar, low to sub-fg/mL
Attomolar, low to sub-fg/mL
Dynamic range
Up to 12 logs across a panel, 6 to 7 logs per individual target (Alamar data)
Up to 12 logs across a panel, 6 to 7 logs per individual target (Alamar data)
Precision
Intra-assay CV under 10% (Alamar data). Study-specific precision confirmed at scoping
Intra-assay CV under 10% (Alamar data). Study-specific precision confirmed at scoping
Sample volume
NULISAseq needs 25 µL per assay, NULISAqpcr needs 35 µL. Ship 35 µL and 45 µL respectively, so dead volume is covered. Confirmed per panel at scoping
NULISAseq needs 25 µL per assay, NULISAqpcr needs 35 µL. Ship 35 µL and 45 µL respectively, so dead volume is covered. Confirmed per panel at scoping
Matrices
Plasma, serum and CSF as standard. Non-standard matrices scoped for feasibility and developed in-house
Plasma, serum and CSF as standard. Non-standard matrices scoped for feasibility and developed in-house
Data output
Relative quantification in NPQ units for NULISAseq panels. Absolute quantitation in pg/mL for Inflammation Panel 250 AQ and NULISAqpcr assays
Relative quantification in NPQ units for NULISAseq panels. Absolute quantitation in pg/mL for Inflammation Panel 250 AQ and NULISAqpcr assays
Deliverables
Normalised data, QC metrics and run documentation. Bioinformatic analysis available
Normalised data, QC metrics and run documentation. Bioinformatic analysis available
Turnaround
Two weeks from sample receipt, NGS and qPCR. Confirmed at quote
Two weeks from sample receipt, NGS and qPCR. Confirmed at quote
Cohort size
Dozens to tens of thousands of samples
Dozens to tens of thousands of samples
Quality framework
HTA licence 12818. GCP-compliant workflows. Aligned to ISO 15189
HTA licence 12818. GCP-compliant workflows. Aligned to ISO 15189
Regulatory status
For research use only. Not for use in diagnostic procedures
Regulatory status
For research use only. Not for use in diagnostic procedures
For research use only. Not for use in diagnostic procedures
Sample requirements
How much to ship
Freeze and thaw
Shipping samples internationally
Sample requirements
How much to ship
Freeze and thaw
Shipping samples internationally
What you gain
Sensitivity that opens new questions
Biomarkers previously below the noise floor become measurable: early neurodegeneration markers, low-circulating cytokines, sub-clinical inflammatory signals.
Sensitivity that opens new questions
Biomarkers previously below the noise floor become measurable: early neurodegeneration markers, low-circulating cytokines, sub-clinical inflammatory signals.
Multiplexing without the trade-off
Up to 340 proteins in a single run. Alamar reports up to 12 logs of dynamic range across a panel and intra-assay CVs under 10%. Per-target quantifiable range is narrower, and we will tell you where your specific targets sit before you commit samples.
Multiplexing without the trade-off
Up to 340 proteins in a single run. Alamar reports up to 12 logs of dynamic range across a panel and intra-assay CVs under 10%. Per-target quantifiable range is narrower, and we will tell you where your specific targets sit before you commit samples.
Precious samples preserved
NULISAseq needs 25 µL and NULISAqpcr needs 35 µL. Ship about 10 µL more than that, so dead volume is covered and a repeat stays possible without recollecting: 35 µL for NULISAseq, 45 µL for NULISAqpcr. We confirm the figure for your panel and matrix at scoping, before anything is shipped. Paediatric studies, longitudinal cohorts, rare disease and biobank aliquots all run into that limit.
Precious samples preserved
NULISAseq needs 25 µL and NULISAqpcr needs 35 µL. Ship about 10 µL more than that, so dead volume is covered and a repeat stays possible without recollecting: 35 µL for NULISAseq, 45 µL for NULISAqpcr. We confirm the figure for your panel and matrix at scoping, before anything is shipped. Paediatric studies, longitudinal cohorts, rare disease and biobank aliquots all run into that limit.
Matrices beyond the standard three
Plasma, serum and CSF as standard. Where your study depends on a matrix Alamar has not validated, we assess feasibility and develop it ourselves. We have strong expertise is handling and validating tricky and novel matrices.
Matrices beyond the standard three
Plasma, serum and CSF as standard. Where your study depends on a matrix Alamar has not validated, we assess feasibility and develop it ourselves. We have strong expertise is handling and validating tricky and novel matrices.
Reproducibility that holds across a cohort
ARGO HT removes manual handling from the workflow. Inter-plate precision then holds when a study runs to thousands of samples, or collects over several years.
Reproducibility that holds across a cohort
ARGO HT removes manual handling from the workflow. Inter-plate precision then holds when a study runs to thousands of samples, or collects over several years.
Sequencing under the same roof
NULISAseq needs an NGS readout. We run it on Element AVITI in our own laboratory, so the samples never leave the building.
Sequencing under the same roof
NULISAseq needs an NGS readout. We run it on Element AVITI in our own laboratory, so the samples never leave the building.
Talk to a scientist about your targets
AVAILABLE PANELS AND ASSAYS
Panels and assays
We run the full NULISA catalogue: high-plex NGS panels, single- and low-plex qPCR assays, and custom assay development for targets outside it.
NGS Panels
qPCR Panels
Custom Assay
NULISAseq CNS Disease Panel 120
NULISAseq Neuro 220 Panel
NULISAseq Immune 340 Panel
NULISAseq Inflammation Panel 250
NULISAseq Inflammation Panel 250 AQ
NULISAseq Mouse Panel 120
120 or more neuro-specific and inflammatory proteins from plasma or CSF. Coverage includes Aβ40 and Aβ42, total tau, p-Tau181, p-Tau217, p-Tau231, NfL, GFAP, synaptic proteins, alpha-synuclein and neuroinflammatory markers.
Choose this when your targets are established and you want focused neurology coverage. Used across Alzheimer's disease, frontotemporal dementia, Lewy body dementia, ALS and progressive supranuclear palsy research.
NGS Panels
qPCR Panels
Custom Assay
NULISAseq CNS Disease Panel 120
NULISAseq Neuro 220 Panel
NULISAseq Immune 340 Panel
NULISAseq Inflammation Panel 250
NULISAseq Inflammation Panel 250 AQ
NULISAseq Mouse Panel 120
120 or more neuro-specific and inflammatory proteins from plasma or CSF. Coverage includes Aβ40 and Aβ42, total tau, p-Tau181, p-Tau217, p-Tau231, NfL, GFAP, synaptic proteins, alpha-synuclein and neuroinflammatory markers.
Choose this when your targets are established and you want focused neurology coverage. Used across Alzheimer's disease, frontotemporal dementia, Lewy body dementia, ALS and progressive supranuclear palsy research.
NGS Panels
qPCR Panels
Custom Assay
NULISAseq CNS Disease Panel 120
120 or more neuro-specific and inflammatory proteins from plasma or CSF. Coverage includes Aβ40 and Aβ42, total tau, p-Tau181, p-Tau217, p-Tau231, NfL, GFAP, synaptic proteins, alpha-synuclein and neuroinflammatory markers. Choose this when your targets are established and you want focused neurology coverage. Used across Alzheimer's disease, frontotemporal dementia, Lewy body dementia, ALS and progressive supranuclear palsy research.
NULISAseq Neuro 220 Panel
Alamar's largest neurology panel, profiling 220 neurodegenerative biomarkers including an extended tau suite. Choose this over the CNS Disease Panel 120 for discovery-scale coverage, where the marker set is not yet fixed.
NULISAseq Immune 340 Panel
Alamar's broadest immune panel, measuring approximately 340 immune-related proteins in a single run. Coverage extends beyond cytokines and chemokines to immune checkpoints, metabolic regulators, cell death mediators and co-stimulatory proteins, at fg/mL to sub-pg/mL concentrations. Choose this when you need the widest view of immune activity: cancer, cardiovascular and metabolic disease, autoimmune disease, and ageing research where chronic low-grade inflammation is the biology of interest.
NULISAseq Inflammation Panel 250
250 cytokines, chemokines, immune checkpoint proteins and inflammatory mediators in a single well. Reports relative quantification in NPQ units, enough to compare samples, groups and timepoints within a study. Choose this over the Immune 340 when your biology is inflammation-focused and the extra breadth would not change your conclusions. Suited to autoimmune research, immuno-oncology, neuroinflammation and translational immunology.
NULISAseq Inflammation Panel 250 AQ
The same 250-target breadth, with absolute quantitation in pg/mL for more than 150 biomarkers alongside relative values for the full panel. Choose AQ when results need comparing against published data, external cohorts or other platforms: PK/PD studies, longitudinal monitoring, and clinical cohorts running across multiple sites and timepoints.
NULISAseq Mouse Panel 120
Inflammation and neurology coverage for murine models, supporting translational bridging between preclinical and clinical proteomics.
Start with your target list
Send us your analytes, matrix and cohort size. We will tell you which panel covers them, where the sensitivity sits for your specific targets, and where any gaps are. That reply comes within one working day.
If NULISA is the wrong platform for your study, we will say so and point you to the right one.
How NULISA pushes below the conventional detection floor
1. Sequential capture and release
Oligonucleotide-conjugated antibodies capture the target, release it, and capture it again. Each step strips away unbound antibody and non-specific complexes, so the background that limits conventional immunoassays is removed before the signal is ever read.
Oligonucleotide-conjugated antibodies capture the target, release it, and capture it again. Each step strips away unbound antibody and non-specific complexes, so the background that limits conventional immunoassays is removed before the signal is ever read.
2. DNA-linked detection
The immunoassay signal is encoded as a DNA barcode. Nothing is read as colour or light. A countable digital signal scales cleanly to hundreds of targets in one well, without the cross-talk that limits conventional multiplexing.
3. qPCR or NGS readout
The same automated platform supports two routes:
qPCR for fast single-plex and low-plex quantification of established biomarkers
NGS for high-plex discovery across large target sets
Programmes can move from broad discovery to focused validation without changing platform, laboratory or antibody pairs, so the data stays comparable across the life of the study.
The same automated platform supports two routes:
qPCR for fast single-plex and low-plex quantification of established biomarkers
NGS for high-plex discovery across large target sets
Programmes can move from broad discovery to focused validation without changing platform, laboratory or antibody pairs, so the data stays comparable across the life of the study.
4. Automated delivery on ARGO HT
The ARGO HT System automates the NULISA workflow, which keeps turnaround short and precision steady across plates.
Cohorts of thousands, and collections that run for years, depend on that.
The ARGO HT System automates the NULISA workflow, which keeps turnaround short and precision steady across plates.
Cohorts of thousands, and collections that run for years, depend on that.
The ARGO HT System automates the NULISA workflow, which keeps turnaround short and precision steady across plates.
Cohorts of thousands, and collections that run for years, depend on that.
1. Sequential capture and release
Oligonucleotide-conjugated antibodies capture the target, release it, and capture it again. Each step strips away unbound antibody and non-specific complexes, so the background that limits conventional immunoassays is removed before the signal is ever read.
2. DNA-linked detection
The immunoassay signal is encoded as a DNA barcode. Nothing is read as colour or light. A countable digital signal scales cleanly to hundreds of targets in one well, without the cross-talk that limits conventional multiplexing.
Is NULISA the right fit for your study?
Choose NULISA when
Your targets sit at very low abundance and conventional immunoassays are running out of sensitivity.
You need broad multiplex profiling across tens or hundreds of targets without losing sensitivity on the low-abundance ones.
You are working with small-volume or precious samples such as CSF, paediatric plasma or biobank aliquots.
You are running discovery or hypothesis-generating work.
You need to screen across a large cohort.
Choose Simoa when
You need a small number of well-established targets quantified with a validated single-molecule method, or an existing dataset was generated on Simoa and comparability matters more than breadth.
More information about Simoa
Choose MSD when
You need mid-plex quantification of higher-abundance analytes, established assay availability, or a cost profile suited to routine measurement across a large sample set.
More information about MSD
Or use more than one
Many programmes run hybrid workflows: broad NULISA discovery, then focused orthogonal validation on Simoa or MSD. Both stages happen here, with one team.
Platform selection is agreed at scoping, before you commit samples.
WHERE
Where NULISA is being used
Neurology and neurodegeneration
Profile amyloid, multiple tau species, NfL, GFAP, synaptic proteins and neuroinflammatory mediators from a single CSF or plasma draw. Used in Alzheimer’s disease, ALS, frontotemporal dementia, Parkinson’s disease, Lewy body disease and rare neurological disorders.
Inflammation, autoimmunity and immuno-oncology
Deep cytokine and chemokine profiling across autoimmune disease, infection, sepsis and immunotherapy response, where sub-clinical inflammatory signals sit below conventional assay sensitivity.
Translational drug development
PK/PD biomarker work, target engagement, toxicology panels, longitudinal monitoring and early-phase clinical trials. Absolute quantitation is often required for regulatory or cross-study comparability.
Rare disease and precious-sample studies
Paediatric cohorts, longitudinal sample sets, biobank material, and any study where sample volume is the rate-limiting reagent.
Biomarker discovery in large cohorts
High-plex multiplexing, automated handling and inter-plate reproducibility support discovery studies extending into thousands of samples.
Neurology and neurodegeneration
Profile amyloid, multiple tau species, NfL, GFAP, synaptic proteins and neuroinflammatory mediators from a single CSF or plasma draw.
Used in Alzheimer's disease, ALS, frontotemporal dementia, Parkinson's disease, Lewy body disease and rare neurological disorders.
Inflammation, autoimmunity and immuno-oncology
Deep cytokine and chemokine profiling across autoimmune disease, infection, sepsis and immunotherapy response, where sub-clinical inflammatory signals sit below conventional assay sensitivity.
Translational drug development
PK/PD biomarker work, target engagement, toxicology panels, longitudinal monitoring and early-phase clinical trials.
Absolute quantitation is often required for regulatory or cross-study comparability.
Rare disease and precious-sample studies
Paediatric cohorts, longitudinal sample sets, biobank material, and any study where sample volume is the rate-limiting reagent.
Biomarker discovery in large cohorts
High-plex multiplexing, automated handling and inter-plate reproducibility support discovery studies extending into thousands of samples.
HOW IT WORKS
How a NULISA project runs with us
1. Scoping conversation
2. Study design and quote
3. Sample receipt and accessioning
4. Assay delivery
5. Data delivery
6. Follow-on validation or extension
THE ALTHEOME DIFFERENCE
Why partner with Altheome on NULISA
NULISA expertise
Sequencing in the same building
Speed as a design principle
Senior scientific oversight
Complementary platforms in-house
Matrices beyond the standard three
One licensed laboratory, end to end
One of five, and the only one in the UK
We have run the platform before we were even certified.
We were the UK's first Alamar Certified Service Provider, and one of the first globally.
THE ALTHEOME DIFFERENCE
Why partner with Altheome on NULISA
NULISA expertise
Sequencing in the same building
Speed as a design principle
Senior scientific oversight
Complementary platforms in-house
Matrices beyond the standard three
One licensed laboratory, end to end
One of five, and the only one in the UK
We have run the platform before we were even certified.
We were the UK's first Alamar Certified Service Provider, and one of the first globally.
THE ALTHEOME DIFFERENCE
Why partner with Altheome on NULISA
NULISA expertise
We have run the platform before we were even certified.
We were the UK's first Alamar Certified Service Provider, and one of the first globally.
Sequencing in the same building
Speed as a design principle
Senior scientific oversight
Complementary platforms in-house
Matrices beyond the standard three
One licensed laboratory, end to end
One of five, and the only one in the UK
Not sure which technology fits your current project?
Send us your targets, matrix and cohort size, and a scientist will advise whether NULISA is the right platform, including when it is not.
Running a multi-study programme? You will hear from us within one working day.